.jpg?w=340&itok=mD6mVzWf "IPT discussed in technical publications."){kind=icon}
Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Will big tech dominate healthcare in the years ahead?
Louisa Roberts, VP of Corporate Development and Partnerships, considers the benefits of partnerships with tech companies.
-
.jpg?w=545&itok=6NQWXVK8 "IPT discussed in technical publications.")
The path to smarter digital health
Michael Phillips and Kevin Rooney discuss the use of artificial intelligence for the purposes of automation in digital health and pharma.
This article is taken from Innovations in Pharmaceutical Technology Autumn/Winter 2021, pages 39-41. Samedan Ltd
-
Data Science: transforming the future of clinical trials
Gerard Quinn, VP of IT Innovation & Informatics, offers insights on the use of Machine Learning and Artificial Intelligence in clinical trials, and the potential benefits and challenges for CROs and sponsors (pages 16-17).
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
ICON’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
-
Role of data in revolutionising the CRO industry
In a wide-ranging interview with PharmaBoardroom, ICON CIO, Tom O’Leary highlights the role of data in revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes.
-
Keeping it Real: Challenges and Benefits of Integrating AI and Machine Learning into Pharma R&D
ICON's CIO Tom O'Leary provides expert commentary on integrating AI and machine learning into Pharma R&D in this January 2020 Bio IT World Article.
-
The Danger of 'Going too far' with AI
Andrew Garrett spoke on a panel at the Financial Times Pharmaceutical & Biotechnology conference, about the recent integration of artificial intelligence (AI) enabled services in pharma R&D.
-
-
Validating Value Data: AI & Outcomes
The application of AI and machine learning in establishing a treatment’s value proposition is still a relatively new concept in pharma. Katya Svoboda, Taneesha Chawla, and Tanvi Ahuja, authors of the ICON whitepaper, The Impact of Artificial Intelligence on Outcomes Based Contracting discuss the challenges and opportunities in the October 2019
-
Can Digital Technologies and AI improve R&D productivity enough to restore ROI?
A thought leadership article authored by Tom O’Leary, exploring what can be done to help ensure return on investment in clinical trials.
